American Journal of Kidney Diseases
Volume 49, Issue 1 , Pages 135-142 , January 2007

EPO Adjustments in Patients With Elevated Hemoglobin Levels: Provider Practice Patterns Compared With Recommended Practice Guidelines

Received 10 May 2006 ,Accepted 22 September 2006.

References 

  1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316:73–78
  2. Eschbach J, Abdulhadi MBJ, Delano B, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease (Results of a phase III multicenter clinical trial). Ann Intern Med. 1989;111:992–1000
  3. US Renal Data System. USRDS 2004 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2004;
  4. National Kidney Foundation. NKF-DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. Am J Kidney Dis. 1997;30(suppl 3):S192–S240
  5. Lacson E, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003;41:111–124
  6. National Kidney Foundation. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis. 2001;37(suppl 1):S182–S238
  7. US Renal Data System. In: USRDS 2005 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005;p. 24;194
  8. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  9. Levy R. The new CMS monitoring policy for anemia drug reimbursement: Implications for providers. Dial Transplant. 2006;35(107):88–89
  10. Collins AJ, Li S, St Peter WL, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001;12:2465–2473
  11. Centers for Medicare & Medicaid Services. 2004 Annual Report, End-Stage Renal Disease Clinical Performance Measures Project. Baltimore, MD: Centers for Medicare & Medicaid Services, Center for Beneficiary Choices; 2004;
  12. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68:1337–1343
  13. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550–560

 Originally published online as doi:10.1053/j.ajkd.2006.09.020 on December 1, 2006.Support: This study was supported by an unrestricted research grant from Amgen Inc, Thousand Oaks, CA. Potential conflicts of interest: A.J.C. and D.T.G. have received consulting fees from Amgen. J.P.E., none.

PII: S0272-6386(06)01520-4

doi: 10.1053/j.ajkd.2006.09.020

American Journal of Kidney Diseases
Volume 49, Issue 1 , Pages 135-142 , January 2007

Article Tools

* Image Usage & Resolution